500371-01-7

Usage

Uses

Used in Organic Synthesis:
4H-Pyran-2-carboxaldehyde, 4-oxo-3-(phenylmethoxy)is used as a building block in organic synthesis for the creation of various organic molecules. Its unique structure allows it to be a key component in the formation of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4H-Pyran-2-carboxaldehyde, 4-oxo-3-(phenylmethoxy)is utilized for the synthesis of pharmaceutical compounds. Its potential role in drug development highlights its importance in medicinal chemistry.
Used in Drug Development:
4H-Pyran-2-carboxaldehyde, 4-oxo-3-(phenylmethoxy)is employed in the development of new drugs and therapeutic agents. Its structural attributes make it a valuable asset in the design and synthesis of novel pharmaceuticals.
Used in Biological Activity Studies:
4H-Pyran-2-carboxaldehyde, 4-oxo-3-(phenylmethoxy)also has the potential to exhibit biological activity. As such, it is used in studies aimed at understanding its pharmacological effects, which could lead to its application in the development of new treatments and therapies.

Upstream product

• 61049-69-2 3-O-benzylmaltol 
• 118-71-8 Maltol 
• 1206102-04-6 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 1206102-05-7 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-pyran-4-one 
• 119736-15-1 2-(hydroxymethyl)-3-(phenylmethoxy)-4H-pyran-4-one 

Downstream Products

• 1315247-50-7 C₂₀H₁₈O₇ 
• 1402887-82-4 N,N',N''-(nitrilotris(ethane-2,1-diyl))tris(3-(benzyloxy)-4-oxo-1,4-dihydropyridine-2-carboxamide) 
• 1229006-25-0 methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyridine-2-carboxylate 
• 1206102-11-5 (4R,12aS)-7-(benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2’:4,5]-pyrazino[2,1-b][1,3]oxazine-9-carboxamide 
• 1051375-16-6 dolutegravir 

Relevant academic research and scientific papers

Polycyclic pyridine oxime-based compound as well as pharmaceutical composition and application thereof

The invention discloses a polycyclic pyridine oxime-based compound and a pharmaceutical composition and application thereof, wherein the polycyclic pyridine oxime-based compound is shown as a formula (I). The compound shows strong inhibition of influenza

PYRIDOPYRAZINE AND PYRIDOTRIAZINE INHIBITORS OF INFLUENZA VIRUS REPLICATION

Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)

Spiro pyridone derivative and application

The invention discloses a spiro pyridone derivative which has a structure shown in a general formula I in the specification. Researches show that the spiro pyridinone derivative has a relatively strong inhibition effect on the activity of influenza A virus RNA polymerase, and can be applied to the preparation of influenza A virus RNA polymerase activity inhibition and influenza A resistance medicines. The general formula I is shown in the specification.

Pyridone [1, 2-b] [1,5] triazepine derivatives as well as preparation and application thereof (by machine translation)

The invention discloses a hydroxypyridone [1, a-b] [1,5] triazepine derivatives as well as preparation and application thereof. Experiments prove that the hydroxypyridinone [1, 2-b] [1,triazepine derivatives (general formula I) have a good inhibition effect on the RNA polymerase activity of influenza A virus RNA, and can be used as an influenza virus RNA polymerase inhibitor to treat influenza caused by influenza virus. General Formula I is as follows. (by machine translation)

Purification and characterization of molybdenum-containing aldehyde dehydrogenase that oxidizes benzyl maltol derivative from Pseudomonas nitroreducens SB32154

Maltol derivatives are used in a variety of fields due to their metal-chelating abilities. In the previous study, it was found that cytochrome P450 monooxygenase, P450nov, which has the ability to effectively convert the 2-methyl group in a maltol derivative, transformed 3-benzyloxy-2-methyl-4-pyrone (BMAL) to 2-(hydroxymethyl)-3-(phenylmethoxy)-4H-pyran-4-one (BMAL-OH) and slightly to 3-benzyloxy-4-oxo-4 H-pyran-2-carboxaldehyde (BMAL-CHO). We isolated Pseudomonas nitroreducens SB32154 with the ability to convert BMAL-CHO to BMAL-COOH from soil. The enzyme responsible for aldehyde oxidation, a BMAL-CHO dehydrogenase, was purified from P. nitroreducens SB32154 and characterized. The purified BMAL-CHO dehydrogenase was found to be a xanthine oxidase family enzyme with unique structure of heterodimer composed of 75 and 15 kDa subunits containing a molybdenum cofactor and [Fe-S] clusters, respectively. The enzyme showed broad substrate specificity toward benzaldehyde derivatives. Furthermore, one-pot conversion of BMAL to BMAL-COOH via BMAL-CHO by the combination of the BMAL-CHO dehydrogenase with P450nov was achieved.

STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES

The present invention provides industrially suitable processes for preparing intermediates in the production of substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity. In the process as shown below, wherein each symbol is as defined in the specification, an optically active substituted tricyclic pyridone derivative of the formula (VII) is obtained in high yield and high enantioselectivity by subjecting a compound of the formula (III) or (VI) to intramolecular cyclization with controlling stereochemistry to obtain a compound of the formula (IV) having a removable functional group on an asymmetric carbon, and then removing the functional group thereof.

Practical and Scalable Synthetic Method for Preparation of Dolutegravir Sodium: Improvement of a Synthetic Route for Large-Scale Synthesis

A practical and scalable synthetic method to obtain dolutegravir sodium (1) was established starting from the readily accessible material maltol (2). This synthetic method includes a scalable oxidation process of maltol and palladium-catalyzed amidation for introduction of an amide moiety, leading to a practical manufacturing method in short synthetic steps. The synthetic method demonstrated herein enables multikilogram scale manufacturing of 1 of high purity.

Intermediate and preparation method thereof

The invention provides a compound as shown in a formula (III). R in the formula is hydrogen atom or hydroxyl protective group. The invention further provides a preparation method of the compound shownin the formula (III), and a preparation method of the compound shown in a formula (I). The compound shown in a formula (IV) is treated as a starting raw material and is reacted with DMF-DMA to obtainthe compound shown in the formula (III); the compound shown in the formula (III) is oxidized to obtain the compound shown in the formula (I). According to the preparation method, raw materials are low in price and easy to obtain; the conditions are mild and are easy to control; the yield is high; few three wastes are generated; massive industrial production can be carried out.

Preparation method of baloxavir marboxil intermediate compound

The invention relates to a preparation method of a baloxavir marboxil intermediate compound. The preparation method includes: using 2-methyl-3-benzyloxy-4-oxo-4-hydropyrane as the initial raw materialand oxygen as the oxidizing agent to perform oxidizing

Hydroxypyridinone and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy

Photodynamic therapy (PDT) is a promising treatment strategy for malignant and nonmalignant lesions. 5-Aminolaevulinic acid (ALA) is used as a precursor of the photosensitizer, protoporphyrin IX (PpIX), in dermatology and urology. However, the effectiveness of ALA-PDT is limited by the relatively poor bioavailability of ALA and rapid conversion of PpIX to haem. The main goal of this study was to prepare and investigate a library of single conjugates designed to coadminister the bioactive agents ALA and hydroxypyridinone (HPO) iron chelators. A significant increase in intracellular PpIX levels was observed in all cell lines tested when compared to the administration of ALA alone. The higher PpIX levels observed using the conjugates correlated well with the observed phototoxicity following exposure of cells to light. Passive diffusion appears to be the main mechanism for the majority of ALA-HPOs investigated. This study demonstrates that ALA-HPOs significantly enhance phototherapeutic metabolite formation and phototoxicity.